Description

Globus Medical: Is the Post-Deal Integration Machine Turning NuVasive and Nevro Into a Real Musculoskeletal Powerhouse?

Globus Medical’s third-quarter 2025 results reflect a balanced blend of growth and strategic maneuvers, marked by notable financial and operational performance. The company posted revenues of $769 million, a robust 22.9% increase compared to the previous year. This growth trajectory was primarily fueled by a 7% increase in the legacy Globus business and contributions from the newly acquired Nevro unit, which added $99.3 million in revenue. Global expansion, particularly in core spinal categories, accompanied by disciplined financial management, drives their strategic framework. Positively, Globus posted a record non-GAAP diluted earnings per share of $1.18, reflecting a 42.6% year-over-year climb, fortified by considerable cash flow generation, culminating in $213.9 million for the quarter. This financial agility allowed Globus to undertake substantial share repurchases amounting to $40 million, reaching a year-to-date total of $256 million.